An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)

Study Overview

The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).

Study Description

Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD).  All study procedures will take place at University Hospital at no cost to you.  You will be compensated for your time and effort.

  • IRB Number: 1902734320
  • Research Study Identifier: TX10435
  • Principal Investigator: Ryan Boente

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.